A Phase 2 interventional study of Inhaled insulin in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2008-02-12.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment, is one of 2 that started in 2004, is one of 11 in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 30 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8 · Phase 4 20
First in 1995; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 60 across the 54 interventional studies. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Diabetes Mellitus, Type 2 by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 62nd largest by enrollment of the 79 interventional ones that give a count, is the only one that started in 2004, is one of 18 in phase 2, and was the 2nd registered.
Pfizer’s Diabetes Mellitus, Type 2 studies by the year they started, since 1999.
3 of the studies testing insulin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, from their registry updates:
Among Pfizer’s 80 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.
(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.
The record gives a start of Nov 2004 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin